IMMV.F Stock Overview
Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.15 |
| 52 Week High | kr0.17 |
| 52 Week Low | kr0.15 |
| Beta | 2.73 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMMV.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 1.2% |
| 1Y | n/a | -0.7% | 24.7% |
Return vs Industry: Insufficient data to determine how IMMV.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how IMMV.F performed against the US Market.
Price Volatility
| IMMV.F volatility | |
|---|---|
| IMMV.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMMV.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMMV.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 11 | Jeff Borcherding | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally. It offers IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) Fundamentals Summary
| IMMV.F fundamental statistics | |
|---|---|
| Market cap | US$8.02m |
| Earnings (TTM) | -US$28.63m |
| Revenue (TTM) | US$145.70k |
55.0x
P/S Ratio-0.3x
P/E RatioIs IMMV.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMV.F income statement (TTM) | |
|---|---|
| Revenue | kr1.58m |
| Cost of Revenue | kr6.68m |
| Gross Profit | -kr5.11m |
| Other Expenses | kr304.33m |
| Earnings | -kr309.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -6.83 |
| Gross Margin | -324.25% |
| Net Profit Margin | -19,646.86% |
| Debt/Equity Ratio | 0% |
How did IMMV.F perform over the long term?
See historical performance and comparison